GEN Receives Ethical Approval to Launch Phase II Clinical Trial for SUL-238 Targeting Mitochondrial Dysfunction in Patients with Parkinson’s Disease
GEN announces approval in the Netherlands to initiate patient enrollment in April 2026 for the Phase II Proof of Concept...